(4R)-3,4-dihydroxy-6-(2-hydroxyethoxy)oxane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4R)-3,4-dihydroxy-6-(2-hydroxyethoxy)oxane-2-carboxylic acid
• 化学式: C₈H₁₄O₇
• 分子量: 222.19
• InChiKey: KJYOAHBUCPDBJU-BJMCJPPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• [EN] CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS<br/>[FR] CONJUGUÉS POUR TRAITER LES MALADIES PROVOQUÉES PAR DES CELLULES EXPRIMANT PSMA
  申请人：ENDOCYTE INC

  公开号：WO2014078484A1

  公开（公告）日：2014-05-22

  The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

  本发明涉及对病原细胞群体进行诊断、成像和/或治疗。具体来说，本发明涉及利用能够靶向PSMA表达细胞的化合物对由PSMA表达细胞引起的疾病，如前列腺癌细胞，进行诊断、成像和/或治疗。
• [EN] COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY<br/>[FR] COMPOSÉS POUR LA TOMOGRAPHIE PAR ÉMISSION DE POSITRONS
  申请人：ENDOCYTE INC

  公开号：WO2015073678A1

  公开（公告）日：2015-05-21

  Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.
• [EN] METHODS OF CONTROLLING ACUTE INFLAMMATORY RESPONSE<br/>[FR] MÉTHODES DE RÉGULATION DE LA RÉPONSE INFLAMMATOIRE AIGUË
  申请人：ENDOCYTE INC

  公开号：WO2021242752A1

  公开（公告）日：2021-12-02

  The present disclosure relates to compositions and methods for use in targeted drug delivery. More particularly, the disclosure is directed to cell-surface receptor binding conjugates for use in controlling or treating inflammatory responses, such as systemic inflammatory response syndrome, cytokine release syndrome, and the like. More particularly, the disclosure is directed to cell-surface receptor binding conjugates for use in controlling or treating COVID-19.